UBS Group’s Boundless Bio BOLD Stock Holding History

UBS Group’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5	Hold	2	–	–	﹤0.01%	11100
2026 Q2	$5	Hold	2	–	–	﹤0.01%	10352
2026 Q1	$2	Sell	2 -21	-91%	-$25	﹤0.01%	10377
2025 Q4	$27	Buy	23 +22	+2,200%	+$27	﹤0.01%	10330
2025 Q3	$1	Sell	1 -12	-92%	-$14	﹤0.01%	10273
2025 Q2	$13	Sell	13 -7,557	-100%	-$10K	﹤0.01%	10143
2025 Q1	$11.4K	Sell	7,570 -8,379	-53%	-$17.4K	﹤0.01%	8555
2024 Q4	$46.3K	Buy	15,949 +12,971	+436%	+$37.8K	﹤0.01%	7349
2024 Q3	$10.3K	Buy	2,978 +1,063	+56%	+$3.85K	﹤0.01%	7733
2024 Q2	$7.41K	Buy	+1,915	New	+$18.3K	﹤0.01%	7854

Other funds holding BOLD

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

UBS Group's BOLD Position: Q3 2026 in Review

UBS Group held its Boundless Bio (BOLD) position steady in Q3 2026 at 2 shares worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #11100.

UBS Group first reported a position in BOLD in Q2 2024 and has held it in 10 quarters since. The position peaked at $46.3K in Q4 2024. 7 funds tracked by Wall St. Rank hold BOLD as of Q3 2026.

UBS Group held 2 shares of Boundless Bio worth $5 as of Q3 2026.
UBS Group left its Boundless Bio share count unchanged in Q3 2026.
Boundless Bio made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #11100 holding.
UBS Group first reported a position in Boundless Bio in Q2 2024 and has held it in 10 quarters since.
UBS Group's Boundless Bio position peaked at $46.3K in Q4 2024.
7 funds tracked by Wall St. Rank held Boundless Bio as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.